Table 1 Associations between patient groups based on ctDNA monitoring and outcome measures

From: Personalized ctDNA detection and genomic profiling in the NeoRHEA Study

Group

RCB 0–2

RCB 3

Odds ratio

Pval

US Yes

US No

OddsRatio

Pval

CCCA

No CCCA

Odds Ratio

Pval

Group 1 (n = 30)

26

4

1

NA

16

14

1

NA

17

7

1

NA

Group 2 (n = 34)

19

15

4.89

0.01

22

12

0.62

0.44

21

3

0.36

0.28

Group 3 (n = 5)

2

3

8.63

0.04

0

5

NA

NA

2

2

2.34

0.57

  1. Group 1: Patients who were ctDNA-negative at baseline, C1D28 and surgery; Group 2: Patients who were ctDNA-positive at baseline and ctDNA-negative at the two subsequent timepoints.
  2. Group 3: Patients who were ctDNA positive at baseline and at least one subsequent time point.
  3. Outcome measures: residual cancer burden (RCB); ultrasound response (US)–yes defined as responders and no defined as Non-responders; Complete Cell Cycle Arrest(CCCA)–CCCA at surgery defined as Ki67 ≤ 2.7% and No CCCA as Ki67 > 2.7%; Group 1 serves as reference group (OR = 1.0) for all comparisons. The statistical test used to calculate p values is Fisher’s exact test.
Back to article page